A Phase 1 Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of PF-04971729 After Administration of Single Escalating Oral Doses Under Fed and Fasted Conditions in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2018
At a glance
- Drugs Ertugliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 24 Mar 2018 Pharmacokinetic and pharmacodynamics results from two studies including this study presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 29 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Dec 2009 Trial location (USA) identified as reported by ClinicalTrials.gov.